Trevena, Inc. is a clinical stage pharmaceutical company focused on discovering and developing the next generation of G-protein coupled receptor (GPCR) targeted medicines.

Trevena, Inc. is a clinical stage pharmaceutical company focused on discovering and developing the next generation of G-protein coupled receptor (GPCR) targeted medicines. Despite the past success of GPCR drugs, there is a significant opportunity to enhance the therapeutic properties of various molecules by specifically activating selected receptor signals. Trevena's expertise lies in understanding which signaling pathways downstream of a GPCR are associated with beneficial versus adverse biological effects. We then utilize that information to discover and optimize "biased ligands" that activate only the beneficial pathways to unlock new biology and avoid drug adverse effects. This approach builds on extensive research from the laboratories of leading scientists in the GPCR field - Robert Lefkowitz, M.D. and Howard Rockman, M.D., at the Duke University Medical Center. Trevena's platform can be broadly applied across multiple therapeutic areas and to date we have discovered novel drug candidates for the treatment of acute heart failure and pain as well as other compounds for treating multiple CNS conditions. The most advanced compound, TRV027, is currently being investigated in phase 2 clinical trials for the treatment of acute heart failure.